Ophthalmalogical-focused developer EyeGate Pharma said this week that the Phase 3 study of its EGP-437 delivered through its EyeGate II drug delivery system did not show non-inferiority to the prednisolone acetate ophthalmic solution control group. The Phase 3 study was evaluating the safety and efficacy of the EGP-437 with the EyeGate II in patients with […]
